These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16392093)

  • 1. How can earlier entry of patients into antiretroviral programs in low-income countries be promoted?
    Lawn SD; Wood R
    Clin Infect Dis; 2006 Feb; 42(3):431-2; author reply 432-3. PubMed ID: 16392093
    [No Abstract]   [Full Text] [Related]  

  • 2. Called to account.
    Aldhous P
    Nature; 2004 Jul; 430(6996):133. PubMed ID: 15241382
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world?
    Lawn SD; Myer L; Wood R
    Clin Infect Dis; 2005 Dec; 41(11):1683-4; author reply 1684. PubMed ID: 16267745
    [No Abstract]   [Full Text] [Related]  

  • 4. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm.
    Moatti JP; N'Doye I; Hammer SM; Hale P; Kazatchkine M
    Nat Med; 2003 Dec; 9(12):1449-52. PubMed ID: 14647513
    [No Abstract]   [Full Text] [Related]  

  • 6. [HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
    Med Klin (Munich); 2003 Jul; 98(7):XV-XVI. PubMed ID: 12945544
    [No Abstract]   [Full Text] [Related]  

  • 7. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closing the affordability gap for drugs in low-income countries.
    Steinbrook R
    N Engl J Med; 2007 Nov; 357(20):1996-9. PubMed ID: 18003957
    [No Abstract]   [Full Text] [Related]  

  • 9. The cost effectiveness of antiretroviral therapy for HIV disease.
    Laurence J
    N Engl J Med; 2001 Jul; 345(1):68; author reply 68-9. PubMed ID: 11439961
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV-1 viral load testing cost in developing countries: what's new?
    Rouet F; Rouzioux C
    Expert Rev Mol Diagn; 2007 Nov; 7(6):703-7. PubMed ID: 18020900
    [No Abstract]   [Full Text] [Related]  

  • 11. AIDS research. Drug trials without the drugs?
    Cohen J
    Science; 2003 May; 300(5623):1212-3. PubMed ID: 12764159
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustaining treatment costs: who will pay?
    Zewdie D; De Cock K; Piot P
    AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744
    [No Abstract]   [Full Text] [Related]  

  • 13. Strategies for the scale-up of antiretroviral therapy in South Africa through health system optimization.
    Barker PM; McCannon CJ; Mehta N; Green C; Youngleson MS; Yarrow J; Bennett B; Berwick DM
    J Infect Dis; 2007 Dec; 196 Suppl 3():S457-63. PubMed ID: 18181694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV/AIDS. The great funding surge.
    Cohen J
    Science; 2008 Jul; 321(5888):512-9. PubMed ID: 18653876
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV resistance and the developing world.
    Gupta RK; Pillay D
    Int J Antimicrob Agents; 2007 May; 29(5):510-7. PubMed ID: 17346940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed-type hypersensitivity skin test reactivity and survival in HIV-infected patients in Uganda: should anergy be a criterion to start antiretroviral therapy in low-income countries?
    Jones-López EC; Okwera A; Mayanja-Kizza H; Ellner JJ; Mugerwa RD; Whalen CC
    Am J Trop Med Hyg; 2006 Jan; 74(1):154-61. PubMed ID: 16407361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug makers to cut prices for developing countries.
    AIDS Alert; 1998 Aug; 13(8 Suppl):1-2. PubMed ID: 11365655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating HIV in the developing world: getting ahead of the drug development curve.
    Ford N; Calmy A; von Schoen-Angerer T
    Drug Discov Today; 2007 Jan; 12(1-2):1-3. PubMed ID: 17198967
    [No Abstract]   [Full Text] [Related]  

  • 19. Pattern, Determinants, and Impact of HIV Spending on Care and Treatment in 38 High-Burden Low- and Middle-Income Countries.
    Granich R; Gupta S; Montaner J; Williams B; Zuniga JM
    J Int Assoc Provid AIDS Care; 2016; 15(2):91-100. PubMed ID: 26715490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uganda cuts AIDS drug deal.
    IAPAC Mon; 2001 Feb; 7(2):40. PubMed ID: 11302022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.